What is Azitra?
Headquartered in Branford, Connecticut, Azitra is a pioneer in the field of precision dermatology. The company utilizes a sophisticated platform that integrates genetic engineering, proteomics, and microbiome research to develop targeted treatments for challenging skin diseases, including Netherton syndrome and ichthyosis vulgaris. By engineering strains of Staphylococcus epidermidis, Azitra creates live biotherapeutic products designed to restore natural skin function. Their proprietary technology, which combines a vast microbial library with artificial intelligence, allows for the rapid identification and development of highly personalized therapeutic candidates, positioning the firm as a leader in next-generation dermatological care.
How much funding has Azitra raised?
Azitra has raised a total of $33.3M across 4 funding rounds:
Debt
$2.1M
Series A
$14M
Debt
$150K
Series B
$17M
Debt (2018): $2.2M with participation from Connecticut Innovations and Bios Partners
Series A (2019): $14M led by Connecticut Innovations, KdT Ventures, Bios Partners, and Godfrey Capital
Debt (2020): $150K supported by PPP
Series B (2020): $17M featuring Connecticut Innovations, Leaps by Bayer, and Bios Partners
Key Investors in Azitra
Connecticut Innovations
Connecticut Innovations is the state's strategic venture capital arm, providing equity and debt financing alongside guidance to help bioscience and technology companies scale effectively.
Bios Partners
Bios Partners is a venture capital firm focused on bringing advanced biotech innovations to market, leveraging deep expertise in clinical drug development to support their portfolio companies.
KdT Ventures
KdT Ventures specializes in early-stage frontier science, investing in transformative technologies across medicine and materials with a focus on fundamental scientific breakthroughs.
What's next for Azitra?
Looking ahead, Azitra is focused on the clinical validation of its lead candidates and the expansion of its therapeutic pipeline. The recent capital infusion will likely be deployed to support ongoing clinical trials and enhance the company's computational biology capabilities. As the firm transitions further into the clinical stage, strategic collaborations will remain a cornerstone of its operational strategy, enabling the scaling of its engineered protein and bacterial platforms. The company's ability to address unmet medical needs in dermatology through its innovative, science-first approach suggests a robust outlook for future commercialization and potential market disruption in the biopharma sector.
See full Azitra company page
